Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 137-142
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.137
Natural history of epithelial ovarian cancer and its relation to surgical and medical treatment
Pierandrea De Iaco, Anna Myriam Perrone, Martina Procaccini, Alice Pellegrini, Philippe Morice
Pierandrea De Iaco, Anna Myriam Perrone, Martina Procaccini, Alice Pellegrini, Gynecologic Oncology Unit, Sant’Orsola Malpighi Hospital, 40138 Bologna, Italy
Philippe Morice, Gynecologic Oncology Unit, Gustave Roussy Institute, 94805 Villejuif, France
Author contributions: All authors contributed equally to this manuscript.
Correspondence to: Pierandrea De Iaco, MD, Gynecologic Oncology Unit, Sant’Orsola Malpighi Hospital, Via Massarenti 13, 40138 Bologna, Italy. pierandrea.deiaco@aosp.bo.it
Telephone: +39-335-6666354 Fax: +39-51-6364392
Received: December 13, 2012
Revised: March 12, 2013
Accepted: April 13, 2013
Published online: November 10, 2013
Processing time: 339 Days and 6.2 Hours
Abstract

Epithelial ovarian cancer (EOC) represents approximately 90% of primary malignant ovarian tumors, the sixth most common cancer in women and the second most common gynecologic cancer. Approximately 80%-85% of all ovarian carcinomas in Western society are serous and up to 95% of patients are in advanced stages (FIGO stage III-IV) at diagnosis. Treatment of ovarian cancer is mainly based on three key approaches: surgical removal of neoplasia; chemotherapy to kill cancer cells; direct chemotherapy on peritoneal surfaces. The application of hyperthermic chemotherapy to the peritoneal cavity (HIPEC) after radical surgery may also be an attractive option. We analyzed the natural history of EOC in the literature and identified various time-points where sensitivity to chemotherapy, freedom from disease and overall survival are different. We propose eight time-points in EOC history with homogeneous oncological findings. The effectiveness of HIPEC in EOC treatment should be evaluated based on these eight time-points and we believe that retrospective and prospective studies of HIPEC should be evaluated according to these time-points.

Keywords: Ovarian cancer; Hyperthermic intraperitoneal chemotherapy; Chemo-sensitivity; Time-points; Survival

Core tip: The standard treatment for advanced ovarian cancer consists in complete cytoreductive surgery and intravenous combination chemotherapy with a platinum compound and a taxane. Although response rates to initial therapy are high, many patients will recur and die of peritoneal carcinomatosis. The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to the standard therapy aims at increasing survival by reducing peritoneal recurrence. In this review we discuss the time points where HIPEC can be proposed.